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Simple Summary: Feline mammary carcinoma (FMC) is the third most common neoplasia in the cat,
showing a highly malignant behavior, with both HER2-positive and triple negative (TN) subtypes
presenting worse prognosis than luminal A and B subtypes. Furthermore, FMC has become a reliable
cancer model for the study of human breast cancer, due to the similarities of clinicopathological,
histopathological, and epidemiological features among the two species. Therefore, the identification
of novel diagnostic biomarkers and therapeutic targets is needed to improve the clinical outcome of
these patients. The aim of this study was to assess the potential of the VEGF-A/VEGFRs pathway, in
order to validate future diagnostic and checkpoint-blocking therapies. Results showed that serum
VEGF-A, VEGFR-1, and VEGFR-2 levels were significantly higher in cats with HER2-positive and TN
normal-like tumors, presenting a positive association with its tumor-infiltrating lymphocytes expres-
sion, suggesting that these molecules may serve as promising non-invasive diagnostic biomarkers
for these subtypes.
Abstract: Vascular endothelial growth factor (VEGF-A) plays an essential role in tumor-associated
angiogenesis, exerting its biological activity by binding and activating membrane receptors, as vascular
endothelial growth factor receptor 1 and 2 (VEGFR-1, VEGFR-2). In this study, serum VEGF-A, VEGFR-
1, and VEGFR-2 levels were quantified in 50 cats with mammary carcinoma and 14 healthy controls.
The expression of these molecules in tumor-infiltrating lymphocytes (TILs) and in cancer cells was
evaluated and compared with its serum levels. Results obtained showed that serum VEGF-A levels were
significantly higher in cats with HER2-positive and Triple Negative (TN) Normal-Like subtypes, when
compared to control group (p = 0.001, p = 0.020). Additionally, serum VEGFR-1 levels were significantly
elevated in cats presenting luminal A, HER2-positive and TN Normal-Like tumors (p = 0.011, p = 0.048,
p = 0.006), as serum VEGFR-2 levels (p = 0.010, p = 0.046, p = 0.005). Moreover, a positive interaction
was found between the expression of VEGF-A, VEGFR-1, and VEGFR-2 in TILs and their serum levels
(p = 0.002, p = 0.003, p = 0.003). In summary, these findings point to the usefulness of VEGF-A and
its serum receptors assessment in clinical evaluation of cats with HER2-positive and TN Normal-Like
tumors, suggesting that targeted therapies against these molecules may be effective for the treatment of
these animals, as described in human breast cancer.
Keywords: feline mammary carcinoma; VEGF-A; VEGFR-1; VEGFR-2; non-invasive biomarkers; an-
giogenesis
1. Introduction
Human breast cancer is the most diagnosed cancer and the leading cause of cancer-
related death in women worldwide [1], being a heterogeneous disease driven by five
distinct molecular profiles (Luminal A, Luminal B, HER2-positive, Triple-Negative Normal
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and Basal-Like) [2,3]. In parallel, the feline mammary carcinoma (FMC) is a very common
neoplasia associated with local recurrence and distant metastasis, resulting in a high
mortality rate [4], being HER2-positive and Triple Negative (TN) the most aggressive
subtypes [5,6]. Furthermore, FMC has become a reliable cancer model for the study of
human breast cancer, due to the similarities of clinicopathological, histopathological and
epidemiological features among the two species [7–9]. Therefore, the development of
new approaches allowing the early detection and appropriate therapeutic strategies and
follow-up of cats with mammary carcinoma becomes crucial.
Angiogenesis, the formation of new blood vessels, is a hallmark of cancer and is
fundamental to supply the high metabolic demands in nutrients and oxygen of cancer cells,
leading to a rapid tumor growth and metastatic dissemination [10,11]. Accordingly, cancer
cells and stromal cells are able to produce and release mediators of angiogenesis, such as the
vascular endothelial growth factor A (VEGF-A) [12–14]. VEGF-A is a glycoprotein (45 kDa)
that is highly conserved among mammalian species, being expressed by different cell
populations, as tumor infiltrating lymphocytes (TILs), macrophages, platelets and cancer
cells, promoting capillary network growth and vascular permeability, allowing cancer cells
to migrate to distinct organs [15–17]. In humans, there are four distinct VEGF-A isoforms
with 121, 165, 189, and 206 amino acids, as a result of alternative mRNA splicing, with
VEGF165 being the predominant isoform [13,18,19]. Several studies in human breast cancer
have shown that VEGF-A overexpression is present in tumors with aggressive phenotype,
such as HER2-positive and TN subtypes [20,21], being associated with poor prognosis and
shorter disease-free survival (DFS) and overall survival (OS) [11,16]. Nevertheless, to show
its biological activity, this angiogenic cytokine needs to bind to specific class-III-membrane
tyrosine kinase receptors expressed on endothelial cells, as the vascular endothelial growth
factor receptor 1 and 2 (VEGFR-1/Flt-1; VEGFR-2/KDR/Flk-1) [22], both having seven
extracellular immunoglobulin homology domains, a transmembrane domain and an in-
tracellular region with a tyrosine kinase domain, leading to distinct biological effects [23].
Accordingly, VEGFR-1 is more related with the pathological angiogenesis, while VEGFR-2
is involved in physiological and pathological angiogenesis [13]. In humans, the interaction
between VEGF-A and VEGFR-2 is the most relevant for angiogenesis in solid tumors [12],
as VEGFR-2 binds to all VEGF-A isoforms [24]. Activated VEGFR-2 promotes the activa-
tion of the PLC-γ, PKC-Raf-1-MEK-MAP kinase and PI3K-AKT pathways, as a signaling
towards cell proliferation and endothelial cell survival [24,25].
Furthermore, it has been described that the secretion of soluble forms of VEGFR-1
(sVEGFR-1) and VEGFR-2 (sVEGFR-2) in the extracellular matrix displayed high affinity to
VEGF-A. These isoforms are considered a natural defense strategy against malignant cells,
exhibiting antiangiogenic, anti-edema and anti-inflammatory effects [13,22]. Accordingly,
a low sVEGFR-1/VEGF-A ratio was associated with higher tumor malignancy and poor
prognosis [13].
The discovery of antitumor immunotherapies targeting tumor-induced angiogene-
sis (e.g., VEGF-A, VEGFR-2) have been proposed as a universal therapeutic strategy to
improve the clinical outcome of patients with several solid tumor types, as breast can-
cer [18,26]. Studies demonstrated that a humanized monoclonal antibody that bind to all
soluble VEGF-A isoforms, bevacizumab, inhibit angiogenesis and tumor growth, promot-
ing significant improvements in DFS of patients with breast cancer [10,27]. However, an
increased overall survival (OS) could not be demonstrated, leading to a bevacizumab’s
approval withdrew by Food and Drug Administration (FDA) after two years following
its initial approval, whereas the European Medicines Agency (EMA) maintained their ap-
proval [10,11]. Furthermore, several novel and potent VEGFR-1 and VEGFR-2 antagonists
are being evaluated in clinical trials, showing promising results [24,28]. In cat, although
Michishita et al. (2016) demonstrated that bevacizumab suppressed tumor growth in
a xenograft model, suggesting its potential therapeutic effect for FMC [29], the role of
VEGF-A in angiogenesis and its biological effects in feline mammary carcinoma is still
poorly documented. Therefore, the aim of this study was to: (i) quantify and compare
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the serum VEGF-A, VEGFR-1 and VEGFR-2 levels between cats with distinct mammary
carcinoma subtypes and healthy controls; (ii) test for associations between serum levels
and clinicopathological features; (iii) evaluate the VEGF-A, VEGFR-1 and VEGFR-2 expres-
sion in TILs and cancer cells of feline spontaneous mammary carcinomas and (iv) screen
for correlations between serum levels and expression levels of VEGF-A, VEGFR-1 and
VEGFR-2 in TILs and cancer cells.
2. Results
2.1. Serum VEGF-A, VEGFR-1 and VEGFR-2 Levels Are Significantly Elevated in Cats with
HER2-Positive and TN Normal-Like Mammary Carcinoma
Cats with mammary carcinoma were stratified according to their tumor subtype and
serum VEGF-A, VEGFR-1 and VEGFR-2 levels were measured and compared with control
group. Results showed that cats with HER2-positive and TN Normal-Like mammary carci-
noma displayed higher serum VEGF-A levels than control group (1748.6 ± 3558.4 pg/mL
vs. 0.0 pg/mL, p = 0.001; 1881.9 ± 2927.9 pg/mL vs. 0.0 pg/mL, p = 0.020; respectively,
Figure 1A). Furthermore, cats presenting Luminal A, HER2-positive and TN Normal-Like
mammary carcinoma subtypes revealed higher serum VEGFR-1 levels, comparing with
healthy group (10197.4 ± 17679.4 pg/mL vs. 0.0 pg/mL, p = 0.011; 3068.9 ± 4935.5 pg/mL
vs. 0.0 pg/mL, p = 0.048; 11527.6 ± 12845.4 vs. 0.0 pg/mL, p = 0.006; respectively, Figure 1B),
as well as serum VEGFR-2 levels (2033.4 pg/mL ± 3550.7 vs. 0.0 pg/mL, p = 0.010;
502.3 ± 1091.8 pg/mL vs. 0.0 pg/mL, p = 0.046; 2023.6 ± 2416.0 pg/mL vs. 0.0 pg/mL,
p = 0.005; respectively, Figure 1C).
Figure 1. Serum vascular endothelial growth factor A (VEGF-A) levels are significantly increased
in cats with HER2-positive and TN Normal-like tumors, while the vascular endothelial growth
factor receptor 1 (VEGFR-1) and 2 (VEGFR-2) are significantly elevated in cats with luminal A,
HER2-positive and TN Normal-like mammary carcinomas. (A) Box plot analysis of serum VEGF-A,
(B) VEGFR-1 and (C) VEGFR-2 levels in the control group and in cats with mammary carcinoma
grouped according to their molecular subtype.
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In addition, a positive correlation was identified between serum VEGF-A and both
VEGFR-1 (r = 0.567, p = 0.0001) and VEGFR-2 levels (r = 0.591, p = 0.0001), and also between
serum VEGFR-1 and VEGFR-2 levels (r = 0.973, p = 0.0001).
2.2. Higher Serum VEGFR-1 and VEGFR-2 Levels are Correlated with the Administration of
Contraceptives and Low-Grade Feline Mammary Carcinomas
A statistical analysis was performed between the serum VEGF-A, VEGFR-1 and
VEGFR-2 levels in cats with mammary carcinoma and the studied clinicopathological
features (Table 1). Although, no significant associations were found between serum VEGF-
A levels and the recorded clinicopathologic parameters, serum VEGFR-1 and VEGFR-2
levels were positively associated with contraceptive administration (p = 0.026 and p = 0.042,
respectively, Figure 2A,B) and tumors of lower malignancy grade (p = 0.037 and p = 0.046,
respectively, Figure 2C,D).
Table 1. Statistical associations between serum VEGF-A, VEGFR-1 and VEGFR-2 levels and clinicopathological parameters













<8 years old 4 (8.0%) 2643.5 ± 5287.0 2442.6 ± 4885.2 337.0 ± 674.1
8–12 years old 26 (52.0%) 159.5 ± 628.1 3771.3 ± 9414.6 754.1 ± 1838.2
>12 years old 20 (40.0%) 738.4 ± 2042.5 5565.3 ± 11,514.6 963.3 ± 2288.2
Spayed
0.075 0.39 0.537
No 24 (48.0%) 1470.3 ± 2914.7 3996.3 ± 8062.8 644.0 ± 1443.7




0.188 0.026 0.042No 21 (42.0%) 660.9 ± 2364.0 1077.3 ± 2740.1 140.4 ± 352.6
Yes 23 (46.0%) 882.9 ± 1900.5 8156.8 ± 12,291.0 1512.1 ± 2413.4
Unknown 6 (12.0%)
Multiple tumors
0.188 0.846 0.701Negative 19 (38.0%) 476.5 ± 1667.7 6572.4 ± 11,690.2 1217.0 ± 2286.1
Positive 31 (62.0%) 989.7 ± 2377.6 3602.3 ± 8396.6 621.3 ± 1617.4
Lymph node status
0.155 0.345 0.432
Negative 31 (62.0%) 1102.7 ± 2557.0 4817.9 ± 9291.5 840.3 ± 1742.9




I 11 (22.0%) 1753.6 ± 3736.3 4766.1 ± 8059.3 882.4 ± 1572.0
II 7 (14.0%) 138.5 ± 339.3 5632.5 ± 11,354.2 993.5 ± 2198.0
III 27 (54.0%) 387.6 ± 1312.0 3609.1 ± 10,349.2 663.2 ± 2051.1
IV 5 (10.0%) 0 6914.8 ± 10,335.0 1213.0 ± 1774.6
Tumor size
0.67 0.374 0.5≤2 cm 26 (52.0%) 835.0 ± 2604.1 6024.2 ± 11,286.1 1140.8 ± 2239.7
>2 cm 24 (48.0%) 467.9 ± 1405.1 2754.6 ± 7646.5 452.9 ± 1386.5
Tumor malignancy
grade
0.198 0.037 0.046I 2 (4.0%) 5286.9 ± 7476.9 20,094.3 ± 14,600.2 3591.6 ± 3172.7
II 6 (12.0%) 0 1899.8 ± 4653.5 278.8 ± 683.0
III 42 (84.0%) 480.0 ± 1526.4 3278.2 ± 9626.1 776.5 ± 1888.2
Tumor necrosis
0.587 0.227 0.182Negative 11 (22.0%) 1358.2 ± 3725.1 8079.7 ± 14,010.3 1640.2 ± 2907.7
Positive 39 (78.0%) 415.3 ± 1549.8 2801.0 ± 8408.6 461.7 ± 1551.2














Negative 43 (86.0%) 544.3 ± 2112.3 0.956 4537.3 ± 10,320.0 0.098 820.5 ± 2011.0 0.117
Positive 7 (14.0%) 941.9 ± 2307.1 0 0
Lymphocytic
infiltration
0.466 0.316 0.523Negative 16 (32.0%) 881.2 ± 2932.7 5173.4 ± 9837.5 901.9 ± 1818.4
Positive 33 (66.0%) 485.1 ± 1669.0 3292.4 ± 9802.5 609.8 ± 1949.4
Unknown 1 (2.0%)
Tumor ulceration
0.073 0.116 0.094Negative 43 (86.0%) 682.0 ± 2286.4 3720.8 ± 9483.9 704.6 ± 1861.9
Positive 7 (14.0%) 161.5 ± 1020.3 4626.6 ± 11,316.9 656.7 ± 2151.0
Metastasis
No 22 (44%) 535.5 ± 198.8 0.89 5740.6 ± 11,041.4 0.165 1093.1 ± 2233.9 0.269
Yes 28 (56%) 747.6 ± 2810.5 3412.8 ± 8447.5 595.1 ± 1526.0
Figure 2. Serum levels of vascular endothelial growth factor receptor 1 (VEGFR-1) and receptor 2 (VEGFR-2) are positively
correlated with the use of contraceptives and lower-malignancy tumors. (A,B) Box-plot analysis showing the mean ± SEM of
serum VEGFR-1 and VEGFR-2 levels and its correlation with the use of contraceptive drugs and (C,D) tumor malignancy grade.
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2.3. Serum VEGF-A, VEGFR-1 and VEGFR-2 Levels Are Positively Associated with Their
Expression in Tumor Infiltrating Lymphocytes
Regarding the above results, the expression of VEGF-A, VEGFR-1 and VEGFR-2 was
analyzed in cancer cells and in tumor infiltrating lymphocytes (TILs). Accordingly, the
immunostaining analysis of cancer cells revealed that 95% (70% weak positive; 25% strong
positive), 19% (17% weak positive; 2% strong positive) and 19% (19% weak positive; 0%
strong positive) of tumors showed a positive score for VEGF-A, VEGFR-1 and VEGFR-2,
respectively. In addition, 51% (33% weak positive; 18% strong positive), 22% (22% weak
positive; 0% strong positive) and 24% (21% weak positive; 3% strong positive) of the tumors
showed a positive IHC staining in TILs for VEGF-A, VEGFR-1 and VEGFR-2. Moreover,
VEGF-A (Figure 3A,B) and VEGFR-1 expression (Figure 3C,D) was detected in cytoplasm
of both cell types, while VEGFR-2 expression (Figure 3E,F) was found in cytoplasm and
nucleus.
Figure 3. Representative images of immunohistochemical staining of vascular endothelial growth
factor (VEGF-A), vascular endothelial growth factor receptor 1 (VEGFR-1) and receptor 2 (VEGFR-
2) in tumor infiltrating lymphocytes and cancer cells of feline mammary carcinomas. Luminal B
subtype graded as TILs negative for (A) VEGF-A, (C) VEGFR-1 and (E) VEGFR-2. Triple Negative
Normal-Like subtype with a TILs-positive score for (B) VEGF-A, (D) VEGFR-1 and (F) VEGFR-2.
Original magnification 400×.
Results also revealed that serum VEGF-A levels were significantly higher in cats
showing a strong positive VEGF-A expression in TILs, in comparison to those with a weak
positive (p = 0.003) or negative (p = 0.003) score (Figure 4A). Furthermore, a positive associ-
ation was found between weak positive VEGFR-1 and VEGFR-2 expressions in TILs and
their correspondent serum levels (p = 0.002, Figure 4B; p = 0.002, Figure 4C). No significant
correlations were found between serum VEGF-A, VEGFR-1, or VEGFR-2 levels and the
expression of these proteins in cancer cells (p = 0.712, p = 0.235, p = 0.218, respectively, data
not shown). In addition, the expression of VEGFR-2 in TILs was associated with high
serum VEGF-A (Figure 4D) and VEGFR-1 (Figure 4E) levels.
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Figure 4. Serum levels and IHC scores of vascular endothelial growth factor (VEGF-A), vascular endothelial growth factor
receptor 1 (VEGFR-1) and receptor 2 (VEGFR-2) in tumor infiltrating lymphocytes (TILs) of cats with mammary carcinoma.
(A) Cats with tumors and a positive score for TILs showed higher serum VEGF-A, (B) VEGFR-1 and (C) VEGFR-2 levels in
comparison with cats that showed a negative score for TILs. (D) Box plot diagrams showing that queens with mammary
carcinomas scored as VEGFR-2-positive TILs had high serum VEGF-A and (E) VEGFR-1 levels.
3. Discussion
Feline mammary carcinoma shows a highly malignant behavior and a poor prognosis,
particularly, the HER2-positive and triple negative subtypes, becoming challenging to
treat due to a lack of specific targets [9,30]. Furthermore, angiogenesis is one of the key
mechanisms involved in cancer progression, which is controlled by several growth factors
secreted by tumor and stromal cells, with VEGF-A being the most potent angiogenic
factor [31,32]. Therefore, in this study, the serum levels and tissue expression of VEGF-A
and its receptors, VEGFR-1 and VEGFR-2, were evaluated in cats with mammary carcinoma,
in order to improve diagnostic tools and therapeutic strategies.
The results showed that serum VEGF-A levels were significantly higher in cats with
more aggressive mammary carcinoma subtypes, i.e., HER2-positive and TN normal-like, in
accordance with previous studies in human breast cancer [19,33–35]. Furthermore, several
studies have shown elevated serum VEGFR-1 and VEGFR-2 levels in breast cancer patients,
Cancers 2021, 13, 117 8 of 13
when compared to healthy controls [22,36,37]. Accordingly, the results obtained in this
study, revealed that cats showing luminal A, HER2-positive, and TN normal-like tumor
subtypes presented higher serum VEGFR-1 and VEGFR-2 levels than control group. This
phenomenon might be explained as a compensatory mechanism for high serum VEGF-A
levels. Indeed, serum VEGFR-1 and VEGFR-2 receptors can bind to all VEGF-A isoforms,
being considered as natural antagonists by decreasing VEGF-A biological activity and its
availability for the membrane-bound receptors [13,22,38]. Moreover, a possible reason for
the elevated serum VEGFR-1 and VEGFR-2 levels found in cats with luminal A subtype
may be related with ulceration. Indeed, all luminal A tumors were ulcerated, suggesting
the development of inflammation and consequently the presence of the soluble forms of
VEGFR-1 and VEGFR-2, in order to exert anti-inflammatory activities [13]. Furthermore,
the results obtained also demonstrated that increased serum VEGFR-1 and VEGFR-2
levels were associated with low-grade tumors, supporting a defense mechanism of these
molecules in initial tumor phases against pathological angiogenesis [38]. However, these
results were observed in only two animals, with more studies being necessary to better
understand this mechanism. Moreover, elevated serum VEGFR-1 and VEGFR-2 levels
were also correlated with contraceptive administration. Accordingly, studies in human
breast cancer demonstrated that oestrogen and progesterone influence both VEGFR-1 and
VEGFR-2 [39,40]. In addition, significant correlations were found between serum VEGF-A
levels and serum VEGFR-1 and VEGFR-2 levels, in accordance with that described for
human breast cancer [22,36].
The immunohistochemical analysis revealed cytoplasmic immunoreactivity for VEGF-
A and VEGFR-1 and cytoplasmic and nuclear staining pattern for VEGFR-2 in cancer cells
and TILs, which is consistent with the results of earlier reports [4,14,18,20]. Furthermore,
results demonstrated that cats with strong positive VEGF-A expression in TILs showed
higher serum VEGF-A levels than cats with a weak positive or negative VEGF-A expres-
sion, suggesting an effective endocrine mechanism for the release of serum VEGF-A from
stromal cells to the bloodstream. Accordingly, as part of tumor microenvironment, TILs
are able to release VEGF-A and inflammatory cytokines, showing immunosuppressive
effects [41], including the formation of new blood vessels by acting on endothelial cells [42]
and enhancing the inflammatory processes by increasing hypoxia inducible factor 1-alpha
(HIF-1α) and VEGF-A synthesis [13]. Moreover, high serum VEGF-A levels were also asso-
ciated with an intense VEGFR-2 reactivity, suggesting that serum VEGF-A also contributes
to the activation of VEGFR-2 [18]. Further, it was identified an association between higher
serum VEGFR-1 levels and its weak positive expression in TILs in FMC samples. This
finding may be related with VEGFR-1 secretion in tumor microenvironment as a soluble
isoform (sVEGFR-1) generated by alternative splicing. Accordingly, Orecchia et al. (2003)
demonstrated that sVEGFR-1 present in tumor microenvironment may also play a protu-
moral action through the stimulation of endothelial cell adhesion and chemotaxis [13,43].
The same could be predicted for VEGFR-2. Finally, sVEGFR-1 can interact with VEGFR-2
abrogating its activity [13]. Whether this provides a compensation mechanism to counteract
the concurrently elevated levels of VEGFR-2 that we observed in TILs infiltrating FMCs
remains to be established.
4. Materials and Methods
4.1. Animal Population and Sample Collection
Fifty animals with spontaneous mammary carcinoma that underwent mastectomy
and fourteen healthy queens presenting for elective ovariohysterectomy were recruited
from Small Animal Hospital of the Faculty of Veterinary Medicine/ULisbon and private
clinics around Lisbon. Tumor samples were collected in accordance with the EU Directive
2010/63/EU and all procedures involving the manipulation of animals were consented by
the owners. All mammary lesions were embedded in paraffin after fixation in 10% buffered
formalin (pH 7.2) during 24–48 h. Serum samples of the same animals were prepared by
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centrifugation of the fresh blood samples at 1500 g for 20 min at 4 ◦C and then aliquoted
and stored at −80 ◦C.
For each animal enrolled in the study, the following clinicopathological characteristics
were recorded: age, breed, reproductive status, contraceptive administration, treatment
performed (none, surgery or surgery plus chemotherapy), number, location and size of tu-
mor lesions, histopathological classification, malignancy grade, presence of tumor necrosis,
lymphatic invasion, lymphocytic infiltration, cutaneous ulceration, regional lymph node
involvement, stage of the disease (TNM system), DFS and OS. The mean age at diagnosis
was 11.8 years (range 7–18 years), while the mean size of the primary lesions was 2.7 cm
(range 0.3–7 cm). The DFS was 8.9 ± 1.1 months (n = 46; 95% CI: 6.8–11.1 months) and the
OS was 13.8 ± 1.3 months (n = 49; 95% CI: 11.1–16.5 months).
Regarding the molecular-based subtyping of FMC [8,9], cats were stratified in five
groups: Luminal A (n = 9), Luminal B (n = 17), HER2-positive (n = 11), TN Normal-Like
(n = 5) and TN Basal-Like (n = 8).
The homology between human and feline VEGF-A121, VEGF-A165 and VEGF-A165b, is
90.8%, 94.2% and 94.1%, respectively (UniProt, accession numbers: Homo sapiens P15692-9,
P15692-4, P15692-8; Felis catus Q95LQ4). Considering the VEGF receptors, the comparison
between human and feline VEGFR-1 and VEGFR-2 revealed a homology of 87.8% and
93.2%, respectively (UniProt, accession numbers: Homo sapiens P17948, P35968; Felis catus
M3WIL9, M3WBW2).
4.2. Quantification of Serum VEGF-A, VEGFR-1 and VEGFR-2 Levels
The assessment of serum VEGF-A, VEGFR-1 and VEGFR-2 levels was performed using
the commercially VEGF (DY293B), VEGF R1/Flt-1 (DY321B) and VEGF R2/KDR (DY357)
DuoSet ELISA kits (R&D Systems, Minneapolis, USA), and following the manufacturer’s
instructions. The absolute levels of VEGF-A, VEGFR-1 and VEGFR-2 were determined
using standard curves (four parameter logistic) run on each ELISA plate. Briefly, the
capture antibodies (100 µL/well) were incubated on 96-well plates overnight, at room
temperature (RT). On the next day, plates were washed three times (3 × 400 µL/well
phosphate buffered saline (PBS)-Tween 0.05%) and coated with 300 µL/well of PBS/BSA
blocking agent (1%, w/v), at RT for 60 min. After another washing step, serum samples
previously diluted (1:20) were added (100 µL/well) and incubated during 2 h at RT. Antigen-
antibody complexes were washed (3 × 400 µL/well PBS-Tween 0.05%) and 100 µL/well
of detection antibodies were added and incubated for 2 h at RT. Then, after three washes
with 400 µL/well of PBS-Tween 0.05%, 100 µL/well of streptavidin-HRP were added and
incubated for 20 min at RT, avoiding placing the microplate in direct light. Afterwards
a further washing step (3 × 400 µL/well PBS-Tween 0.05%), 100 µL/well of substrate
solution (1:1 mixture of H2O2 and tetramethylbenzidine) were added and incubated for
20 min at RT in the dark, followed by a stop solution (50 µL/well of 2 N H2SO4). A
microplate reader was used to measure the optical density at 450 nm and 570 nm (Fluostar
Optima Microplate Reader, BMG, Ortenberg, Germany). Standards and negative controls
were run on each ELISA plate.
4.3. Immunohistochemistry Staining and Evaluation
Immunohistochemistry was done on 3 µm thickness sections of FMC samples (Micro-
tome Leica RM2135, Newcastle, UK). Deparaffinization, rehydration and antigen retrieval
were performed using a PT-Link module (Dako, Agilent, Santa Clara, CA, USA), by boiling
glass slides in Antigen Target Retrieval Solution pH 9 from Dako, during 20 min at 96 ◦C.
Then, slides were cooled for 30 min at RT and rinsed twice for 5 min in distilled water.
Thereafter, sections were blocked with Peroxidase Block Novocastra Solution (Novacastra,
Leica Biosystems, Newcastle, UK) during 15 min at RT, followed by two washing steps
with PBS pH 7.4, and Protein Block Novocastra Solution (Leica Biosystems) during 10 min.
After two washes with PBS for 5 min, tissue slides were incubated with the primary anti-
bodies (Table 2). After incubation, each tissue section was washed with PBS 2x for 5 min
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and subsquently treated with the Post-Primary Reagent (Leica Biosystems) for 30 min at
RT and with the Novolink Polymer (Leica Biosystems) for 30 min. Afterwards, sections
were stained with DAB Chromogen Solution (Leica Biosystems) for 5 min and nuclei were
counterstained with Gills hematoxylin (Merck, NJ, USA). Slides were dehydrated in an
ethanol gradient and mounted with Entellan mounting medium. Human and feline kidney
tissues were used as negative and positive controls. Positive and negative control samples
were included in each slide run.
Table 2. Primary antibodies and their conditions of use.
Monoclonal Antibody Reference Dilution Incubation Time and Temperature
Anti-VEGF Clone VG1 (Novus Biologicals) 1:50 60’ at RT
Anti-VEGFR1/Flt-1 Clone CL0345 (Novus Biologicals) 1:200 60’at RT
Anti-VEGFR2/KDR/Flk-1 Clone EIC (Novus Biologicals) 1:10 120’ at RT plus 4 ◦C overnight
RT—Room Temperature.
The staining of VEGF-A, VEGFR-1 and VEGFR-2 in tumor-infiltrating lymphocytes
and cancer cells was assessed manually by two independent pathologists. TILs were
identified by their characteristic morphology and scored according to the International
TILs Working Group 2014 [44]. Furthermore, cancer cells were evaluated in whole tumor
sections with 200–400× magnification. The percentage of positive staining cells was scored
using a 4-point scale: 0 (<10%), 1 (10–25%), 2 (26–50%) and 3 (>50%) and the staining
intensity was graded as: 0 (no staining), 1+ (weak), 2+ (moderate), and 3+ (strong). The
percentage of positive cells and intensity score were then added to obtain a final IHC
score [20]. IHC scores of 0–3 were defined as negative, 4–5 as weak positive and 6 as strong
positive (Table 3).
Table 3. Scoring criteria of immunostaining assay for VEGF-A, VEGFR-1 and VEGFR-2.
Percentage of Positive Staining Cells Staining Intensity
Score Interpretation Score Interpretation
0 <10% 0 No staining
1 10–25% 1 Weak
2 26–50% 2 Moderate
3 >50% 3 Strong





Statistical analysis was performed using the SPSS software version 25.0 (IBM, Armonk,
NY, USA), while the GraphPad Prism version 8.1.2 (GraphPad Software, CA, USA) was
used to plot the graphs. The non-parametric Mann–Whitney U test and the Kruskal–Wallis
test were carried out to analyze the differences among groups of continuous variables.
Correlations between variables were performed using the Spearman’s rank coefficient.
Outliers with more than three standard deviations were removed from analysis. Results
with a p-value < 0.05 were deemed to be statistically significant.
5. Conclusions
In conclusion, cats with HER-2 positive and TN Normal-Like mammary carcinoma
subtypes showed more elevated serum VEGF-A, VEGFR-1, and VEGFR-2 levels than
healthy animals, suggesting that these molecules may serve as promising non-invasive
diagnostic biomarkers for these subtypes. Furthermore, circulating VEGF-A together with
its receptors was positively associated with its expression in TILs, indicating that, besides
Cancers 2021, 13, 117 11 of 13
hypoxia, inflammation is another mechanism that leads to cancer progression via VEGF-
A/VEGFRs signaling. Altogether, the similarities found between FMC and human breast
cancer further validate the utility of the cat as a valuable model for comparative oncology
studies.
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